Summary
The improved cardiac function in patients with congestive heart failure treated with coenzyme Q10 supports the hypothesis that this condition is characterized by mitochondrial dysfunction and energy starvation, so that it may be ameliorated by coenzyme Q10 supplementation. However, the main clinical problems in patients with congestive heart failure are the frequent need of hospitalization and the high incidence of life-threatening arrhythmias, pulmonary edema, and other serious complications. Thus, we studied the influence of coenzyme Q10 long-term treatment on these events in patients with chronic congestive heart failure (New York Heart Association functional class III and IV) receiving conventional treatment for heart failure. They were randomly assigned to receive either placebo (n = 322, mean age 67 years, range 30–88 years) or coenzyme Q10 (n = 319, mean age 67 years, range 26–89 years) at the dosage of 2 mg/kg per day in a 1-year double-blind trial. The number of patients who required hospitalization for worsening heart failure was smaller in the coenzyme Q10 treated group (n = 73) than in the control group (n = 118, P < 0.001). Similarly, the episodes of pulmonary edema or cardiac asthma were reduced in the control group (20 versus 51 and 97 versus 198, respectively; both P < 0.001) as compared to the placebo group. Our results demonstrate that the addition of coenzyme Q10 to conventional therapy significantly reduces hospitalization for worsening of heart failure and the incidence of serious complications in patients with chronic congestive heart failure.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Cohn JN, Johnson G, Ziesche S et al. (1991) A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325:303–310
Di Somma S, Carati L (1991) Efficacy of coenzyme Q in association with conventional therapy in the treatment of heart failure and ischemic heart disease. In: Biomedical and clinical aspects of coenzyme Q10. Elsevier, Amsterdam, pp 257–265
Folkers K, Vadhanavikit S, Mortensen SA (1985) Biochemical rationale and myocardial tissue data on the effective therapy for cardiomyopathy with coenzyme Q10. Proc Natl Acad Sci USA (1985) 82:901–904
Langsjoen PH, Vadhanavikit S, Folkers K (1985) Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q10. Proc Natl Acad Sci USA 82:4240–44
Langsjoen PH, Langjoen PH, Folkers K (1991) Long-term efficacy and safety of coenzyme Q10 therapy for idiopathic dilated cardiomyopathy. In: Biomedical and clinical aspects of coenzyme Q10. Elsevier, Amsterdam, pp 241–246
Littarru GP, Ho L, Folkers K (1972) Deficiency of coenzyme Q10 in human heart disease. I, II. Intern J Vit Nutr Res 42:291, 413
Mortensen SA, Kondrup J, Folkers K. (1991) Myocardial deficiency of coenzyme Q10 and carnitine in cardiomyopathy. Biochemical rationale for concomitant coenzyme Q10 and carnitine supplementation. In: Biomedical and clinical aspects of coenzyme Q10. Elsevier, Amsterdam, pp 269–281
Richardson PJ, Atkinson L (1980) In: Bolte H-D (ed) Myocardial biopsy. Diagnostic significance. Springer, Berlin Heidelberg New York, pp 97–101
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Morisco, C., Trimarco, B. & Condorelli, M. Effect of coenzyme Q10 therapy in patients with congestive heart failure: a long-term multicenter randomized study. Clin Investig 71 (Suppl 8), S134–S136 (1993). https://doi.org/10.1007/BF00226854
Issue Date:
DOI: https://doi.org/10.1007/BF00226854